PubMed Health⌕ Search

Biomedical subjects

C Kornetsky

Publications and source records attributed to C Kornetsky.

At least 19 recordsLinked to original sources
PubMed1996

Naloxone alters the local metabolic rate for glucose in discrete brain regions associated with opiate withdrawal.

The current 2-deoxy-D-[1-14C]glucose investigation was performed to test the hypothesis that endogenous opioids influence basal synaptic activity within discrete brain regions. To examine this hypothesis, the effects of naloxone (1.0 mg/kg s.c.) on local cerebral metabolic rate for glucose (LCMRglu) in 84 brain regions were compared to saline controls. The specificity of naloxone's effects for opioid receptors was assessed by the coadministration of the opiate agonist morphine in a separate group. In naloxone-treated rats, there was a significant decrease in LCMRglu in the locus coeruleus (LC) and an increase in the central nucleus of the amygdala (CAMY), supporting a tonic influence of endogenous opioids on these regions. These metabolic changes were reversed by coadministered morphine, indicating that naloxone's metabolic actions are specific for opioid receptors. Based on the role of the LC and CAMY in opiate withdrawal, the present results suggest a subthreshold naloxone precipitated withdrawal from endogenous opioids. Although morphine administered alone significantly reduced LCMRglu in 16 brain regions, these did not include the LC or the CAMY. These results identify brain regions in which synaptic activity is under tonic modulation by endogenous opioids.

Amygdala↗
PubMed1996

Reexpression of morphine-induced oral stereotypy six months after last morphine sensitizing dose.

We describe three experiments, two of which were designed to determine the duration of the sensitization to morphine-induced oral stereotypy caused by three high doses of morphine (MS) administered 12 h apart (10, 20, and 20 mg/kg). In one of these experiments, we also administered an additional 40 mg/kg. The third experiment was designed to determine the role of mode of drug administration in the development of MS-induced sensitization; drug was delivered by an implanted minipump. By the third high dose, all rats manifested marked repetitive gnawing and biting behavior. The stereotypy was reexpressed up to over 300 days in repeatedly challenged animals and up to at least 180 days in animals receiving only one MS challenge. The development of sensitization was not altered by the mode of drug administration.

Animals↗
PubMed1995

The effect of MK-801 and SCH23390 on the expression and sensitization of morphine-induced oral stereotypy.

Repeated high doses of morphine sulfate, administered in a 24-36 h period, stimulates the expression of oral stereotypy in rats. Sensitization to this effect of morphine is demonstrated by the reexpression of the stereotypy by the administration of 4.0 mg/kg of morphine one week following the original exposure. To investigate the role of N-methyl-D-aspartic acid (NMDA) and D1 dopamine (DA) receptors in the acute expression and sensitization of morphine-induced oral stereotypy, rats were administered four injections of morphine (10.0 mg/kg) one injection every 12 h and observed for the expression of stereotypic behaviors following pretreatment with selective antagonists. Pretreatment with the NMDA antagonist, MK-801 (0.7 mg/kg), before each of the four morphine injections antagonized both the initial expression of oral stereotypy and the development of sensitization. In contrast, the DA D1 receptor antagonist SCH23390 (40.0 micrograms/kg) administered during the four high-dose treatments with morphine antagonized the initial expression of oral stereotypy and not the development of sensitization. These findings implicate glutamate's action at the NMDA receptor in both the acute expression of morphine-induced oral stereotypy, and the development of sensitization of this morphine effect, whereas DA D1 receptors may only be involved in the acute expression of the stereotypy.

Animals↗
PubMed1994

The local cerebral metabolic effects of morphine in rats exposed to escapable footshock.

The 2-deoxy-D-[1-14C]glucose (2-DG) method was used to examine the effects of morphine sulfate (MS) on local cerebral metabolic rates for glucose (LCMRglu) in male F-344 rats required to turn a wheel manipulandum in order to escape from nociceptive footshock. Four groups of rats were studied: control-saline, control-MS, footshock-saline and footshock-MS. All animals were administered MS (4 mg/kg, s.c.) or saline 7 days, 3 days and 10 min prior to the start of the 2-DG experiment. In agreement with its well-known effect on the emotional component of pain, MS administered to rats exposed to footshock caused a significant decrease in LCMRglu compared to footshock-saline rats in limbic structures such as the diagonal band of Broca, lateral septum, bed nucleus of the stria terminalis, horizontal limb of the diagonal band, habenular complex and medial amygdala. Additionally, two components of the midline thalamus with extensive connections with the limbic system, the paraventricular and paratenial thalamic nuclei, were similarly affected by morphine. Footshock caused an overall increase in cerebral metabolism as 52 of 73 measured structures demonstrated increases in activity compared to saline control; however, statistically significant effects in specific structures were limited. These results identify limbic and midline thalamic structures important in morphine-induced analgesia and indicate that footshock tends to have a generalized stimulatory effect on LCMRglu.

Animals↗
PubMed1994

Lack of hepatotoxicity with naltrexone treatment.

Naltrexone, a specific opiate receptor antagonist, is used clinically in the treatment of heroin addiction and more recently, for the treatment of dyskinesia associated with Huntington's disease (HD). Naltrexone may act as a potential hepatotoxin, as reflected in the elevation of transaminase levels. However, one study concluded that, for a brief treatment period of 12 weeks, there is no contraindication to naltrexone treatment based solely on increased hepatic enzyme values. This study monitored liver transaminase levels, in ten HD patients receiving daily doses, between 50 mg/day and 300 mg/day, of naltrexone for periods of 10 to 36 months. Serum glutamic oxalacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) levels were obtained before treatment and at intervals of 1 to 4 months during treatment. Only one of the ten patients treated with naltrexone had increased levels of both SGOT and SGPT, whereas one other patient showed elevated levels of SGPT. These elevations, which initially appeared dose related decreased to normal limits with continued treatment. Because many of the patients were receiving other medications, a combination of drugs with naltrexone may contribute to the increased transaminase levels seen in two of the patients. In summary, chronic administration of naltrexone in doses up to 300 mg/day for periods up to 36 months does not significantly change hepatic function, as measured by SGOT and SGPT levels.

Adult↗
PubMed1994

Bromocriptine, a D2 receptor agonist, lowers the threshold for rewarding brain stimulation.

Drug-induced lowering of brain stimulation reward threshold can serve as a model for the pharmacological activation of reward pathways. Here, the effects of bromocriptine, a direct D2 dopamine receptor agonist, on reward thresholds were investigated. Bromocriptine administration resulted in the significant lowering of threshold levels in all test animals, suggesting that this agent can activate the same reward processes as do abused substances such as cocaine and morphine.

Animals↗
PubMed1993

Nicotine and brain-stimulation reward: interactions with morphine, amphetamine and pimozide.

Using a rate-independent discrete trial method of determining thresholds for rewarding electrical intracranial stimulation in rats, we evaluated the pharmacological interaction of nicotine plus morphine, d-amphetamine, or the D2 receptor antagonist, pimozide. Both morphine and amphetamine shifted the dose-response curve for nicotine down and to the left, indicating increased efficacy and potency, respectively. Pimozide at doses that have no effect on performance and only minimal effect on brain-stimulation reward blocked the effect of nicotine. These data suggest that the same dopaminergic substrate that supports the positive reinforcing effects of other drugs of abuse also supports nicotine reward.

Amphetamine↗
PubMed1992

Effects of nicotine on the threshold for rewarding brain stimulation in rats.

The rewarding effects of nicotine alone and nicotine challenged with mecamylamine, a nicotine receptor blocker, or naloxone were determined using a rate-independent discrete-trial threshold measure of brain-stimulation reward in rats. If nicotine acts as other drugs of abuse, it would be expected to lower the reward threshold, that is, increase an animal's sensitivity to rewarding brain stimulation, and naloxone would be expected to block this effect, as it does other stimulants in this paradigm. Nicotine was found to significantly lower the reward threshold and mecamylamine blocked this effect. However, although naloxone increased the variability of nicotine's effect on the reward threshold, it failed to dose dependently block nicotine's threshold-lowering effect.

Animals↗
PubMed1992

Brain mechanisms of drug-induced reinforcement.

The results of the experiments described above suggest that although the abused psychomotor stimulants and opioids have independent actions that contribute to their reinforcing effects, there are common neuronal substrates for some of their rewarding effects. Additionally there is considerable evidence implicating dopamine systems in these rewarding effects. The neuronal systems involved in these pharmacological actions may be similar to those involved in the rewarding effects of electrical stimulation to the brain. Although both classes of compounds cause euphoria in humans and are reinforcing in animals, the opioids are also central nervous system depressant drugs. These depressant properties influence the subjective effects in humans and possibly the nature of the rewarding effect in animals. Experiments using the 2-deoxyglucose procedure indicate that BSR to either the ventral tegmental area or the medial forebrain bundle results in functional activation throughout the mesocorticolimbic system. The major effects are found in the nucleus accumbens, olfactory tubercle, and the medial prefrontal cortex. Cocaine produces increases in metabolic rates similar in distribution to BSR. Morphine, however, only causes significant increases in functional activity in the olfactory tubercle. Further, only in this brain site did the combination of BSR plus morphine or cocaine cause increases in functional activity over that of stimulation alone. These findings suggest that the olfactory tubercle plays a major role in the pharmacological actions of both the psychomotor stimulants and the opioids as well the rewarding effects of electrical stimulation of the brain.

Animals↗
PubMed1992

Brain-stimulation reward: a model for the study of the rewarding effects of abused drugs.

The robustness of the findings of the BSR effects of abused substances indicates that almost any technique used to measure these effects will be useful. The simplest procedure, however, of selecting a single intensity of stimulation and determining the effects of drugs on the rate of response for that selected intensity is fraught with difficulty in interpretation. More than 25 years ago the interpretation of changes in response rate as a reflection of changes in the reward value of the stimulation was challenged (Hodos and Valenstein 1962). Today it is rare to see a single stimulation intensity used in a published manuscript. However, most studies still use procedures of which rate of response is an integral part. Because animals will press a lever more than 80 times per minute and--on a continuous reinforcement schedule--receive as many as 80 stimulations a minute, conclusions about the specificity of the effects of drugs are difficult. The results of BSR experiments on mechanisms of action of abused substances clearly indicate that the reinforcing effect of most, if not all, such substances is probably the result of activation of a reward system that originates in the cell bodies of the ventral tegmental area and courses rostrally to the limbic and frontal projection sites of the mesocortical system. Thus, we believe, the technique has clearly fulfilled its promise as a "window on the brain" (Olds 1977).

Animals↗
PubMed1992

Heroin, 6-acetylmorphine and morphine effects on threshold for rewarding and aversive brain stimulation.

Studies investigating the reinforcing and analgesic activity of heroin and morphine have found that heroin is a more potent compound. The rapid deacetylation of heroin to 6-acetylmorphine and morphine raises questions concerning the underlying mechanism responsible for this difference in potency. The present series of experiments addressed this issue by examining, in the rat, the relative potency of heroin and its active metabolites, 6-acetylmorphine and morphine, to lower the threshold for rewarding stimulation of the medial forebrain bundle and raise the threshold for aversive stimulation of the mesencephalic reticular formation. Reward and escape thresholds were determined by using a modification of the psychophysical method of limits. Heroin was found to be approximately 40 times more potent than morphine in lowering the reward threshold and approximately 6.5 times more potent in raising the escape threshold. 6-Acetylmorphine and heroin were approximately equipotent in producing significant effects on the threshold for both rewarding and aversive brain stimulation. These findings suggest that heroin's increased potency when compared to morphine may be due, in part, to the activity of 6-acetylmorphine.

Animals↗
PubMed1991

The role of the olfactory tubercle in the effects of cocaine, morphine and brain-stimulation reward.

Using the quantitative 2-[14C]deoxyglucose autoradiographic method, local rates of glucose utilization were measured in rats after the administration of morphine or cocaine in the presence or absence of rewarding brain stimulation to the medial forebrain bundle. In animals that did not receive brain stimulation, cocaine significantly increased glucose utilization in the olfactory tubercle, medial prefrontal cortex and substantia nigra pars reticulata, whereas morphine significantly increased glucose metabolism in the olfactory tubercle only. Stimulation itself increased metabolic rates in a number of sites, such as the olfactory tubercle, nucleus accumbens, medial prefrontal cortex, ventral tegmental area and others. However, in self-stimulating animals both morphine and cocaine caused further increases in activity in the olfactory tubercle. Since the olfactory tubercle was the only structure to cause a significant increase in metabolic rate following each treatment, the results implicate this limbic structure in the rewarding effects of morphine, cocaine and brain-stimulation reward.

Animals↗
PubMed1991

L-histidine attenuates the effects of pentazocine on rewarding brain-stimulation.

Previous research has indicated that the antihistamine tripelennamine potentiates the threshold lowering effects of pentazocine on brain stimulation reward, a model of drug-induced euphoria. To determine the importance of histamine in this interaction, we studied the effects of co-administration of L-histidine and pentazocine on the threshold for brain stimulation reward. Pentazocine (2.5-10.0 mg/kg) lowered the threshold for rewarding stimulation to the medial forebrain bundle-lateral hypothalamus in male F344 rats. L-histidine (500 and 750 mg/kg) by itself had no significant effects, yet antagonized the threshold lowering effects of pentazocine. These doses of L-histidine are known to significantly raise brain histamine concentrations. Our results suggest that histamine may play a tonic inhibitory role, at least in part, on the neural systems responsible for the reinforcing properties of pentazocine.

Animals↗
PubMed1991

Naloxone prevents and blocks the emergence of neuroleptic-mediated oral stereotypic behaviors.

A commonly used animal model for tardive dyskinesia is the oral stereotypy that is expressed by a challenge dose of a dopamine agonist after daily administration of dopamine antagonists (neuroleptics). In the first of two experiments the expression of this dopamine agonist-induced oral stereotypy was prevented by the concomitant administration of the opiate antagonist naloxone. In a second experiment, if the stereotypy was allowed to be expressed, it could be blocked by the administration of naloxone. To the extent that the effects of chronic neuroleptic treatment in rats is a model for tardive dyskinesia, the results suggest that administration of naloxone can both prevent and block the dyskinetic syndrome associated with neuroleptic use.

Animals↗
PubMed1990

The distribution of changes in local cerebral energy metabolism associated with brain stimulation reward to the medial forebrain bundle of the rat.

Using the quantitative 2-[14C]deoxyglucose autoradiographic method, local rates of glucose utilization were measured in rats during brain stimulation reward to the medial forebrain bundle. Metabolic activation was observed both rostral and caudal to the site of stimulation. These sites included the nucleus accumbens, olfactory tubercle, lateral septum, and ventral tegmental area. In many cases, increases in glucose utilization occurred bilaterally. These data suggest the involvement of both ascending and descending systems in brain stimulation reward. Furthermore, despite the unilateral nature of the electrical stimulation, increases in glucose utilization were observed both ipsilateral and contralateral to the site of stimulation.

Animals↗